For more than thirty years, Penta has worked to ensure that pregnant people, infants, children and adolescents are no longer left behind in the fight against infectious disease. In 2025, despite an increasingly challenging global environment, this commitment continued to guide our work.
The 2025 Annual Report report presents the main activities and achievements over 2025 and outlines the priorities guiding our work in the years ahead.
Our results in 2025
Click to enlarge image.
Key milestones of 2025
Click on the icons to know more about our 2025 achivements.
EPPICC Dolutegravir study completed, advancing evidence for paediatric HIV care
Completion of enrolment in the THAI-CARES study, generating evidence where the burden is highest
UNIVERSAL study completed, accelerating access to child‑friendly HIV treatment options
VERDI project completed, delivering policy recommendations on inclusive infectious disease research
Launch of the PIPELINE project to strengthen pregnancy and infant preparedness
Registration under NIS2 with designation as an “Important Entity”
Capacity building within the THRIVE project to strengthen Advanced HIV Disease (AHD) care in paediatrics
PentaTr@ining celebrates its 20th anniversary
SNIP-AFRICA project embeds families and caregivers at the heart of neonatal sepsis research
Penta Young Reporters project wins Communiqué Award for Excellence in Patient Engagement
Advancing research on pregnancy and child health in 2025
In 2025, Penta continued to strengthen its role as a global leader in infectious disease research for pregnancy and child health populations.
Read reflections from Chiara Messina, Penta’s Head of Program Operations, about how Penta has leveraged multidisciplinary collaborations to address critical knowledge gaps and ensure that populations often excluded from clinical research remain central to advances in therapies and public health strategies.
Guiding science with responsibility: Penta’s 2025–2029 scientific strategy
In a rapidly evolving, highly interconnected global health landscape, Penta’s role extends beyond generating knowledge. We must include underrepresented regions and underserved groups, actively reflect the voices of communities, patients, and families, uphold the highest ethical standards, and produce responsive research that delivers lasting value for individuals, families, and society.
Read this article written by Ali Judd and Pablo Rojo, co-chairs of the Penta Scientific Steering Committee, outlining how our commitment to equitable, collaborative and future-focused infectious disease research is embedded within Penta’s 2025-2029 scientific strategy.
Investing in our people: career progression and personal growth
At Penta, we recognise that our success depends on the talent, dedication and well‑being of our staff. In line with our Gender Equality Plan 2025-2027, we continuously strive foster a diverse, equitable and inclusive working environment where everyone feels valued as an individual and supported in their professional development.
But the best way to understand our culture is through the voices of our team. Read Giorgia Dalla Valle‘s story about her Master of Science in Public Health at the London School of Hygiene & Tropical Medicine (LSHTM), supported through Penta’s Education Call, and discover how professional growth and personal development are fostered within our organisation.
What does the future hold for Penta?
Looking ahead, we are expanding our research horizon by strengthening the integration between basic science, translational research and clinical trials.
Read this article by Paolo Palma, Co‑Scientific Coordinator at Vaccinopolis and Chair of Paediatrics at the University of Rome “Tor Vergata”, about how Penta can act as key player in pandemic and infectious disease preparedness, using its expertise in paediatric and maternal infectious diseases to advance both vaccines and monoclonal antibodies as complementary prevention tools.
Our financial results
Expenses by type of activity
This chart illustrates the percentage distribution of our resource allocation across different activities for 2025. As shown, the largest share of expenditure is devoted to the organisation’s core mission, demonstrating a clear prioritisation of research activities, supported by a relatively lean structure for general and financial operations.
Revenues by funder
Penta benefits from strong partnerships with a variety of funding sources. Private funding accounts for the majority of our funding while public funding contributed for about 27% of overall revenues, providing a solid and stable institutional funding base. Overall, the funding composition demonstrates a clear reliance on private funding, complemented by significant public support and minor contributions from training and ancillary activities, resulting in a balanced and sustainable revenue profile.
Our previous Annual Reports
- Annual Report 2024
- Penta Foundation’s 2024 Financial Statements (pdf)
- Report of the Independent Auditor (pdf)
- Comunicazione ai sensi Art. 1 commi 125–129 Legge 06.04.22 N. 124 (pdf)
- Annual Report 2023
- Report of the independent auditor (pdf)
- Remunerations of the statutory bodies (pdf)
- Comunicazione ai sensi Art. 1 commi 125–129 Legge 06.04.22 N. 124 (pdf)
- Annual Report 2022
- Penta Foundation’s 2022 Financial Statements (pdf)
- Report of the Independent Auditor (pdf)
- Remunerations of the statutory bodies (pdf)